153 related articles for article (PubMed ID: 33347896)
1. Characterization of hyperglycemia in patients receiving immune checkpoint inhibitors: Beyond autoimmune insulin-dependent diabetes.
Leiter A; Carroll E; Brooks D; Ben Shimol J; Eisenberg E; Wisnivesky JP; Galsky MD; Gallagher EJ
Diabetes Res Clin Pract; 2021 Feb; 172():108633. PubMed ID: 33347896
[TBL] [Abstract][Full Text] [Related]
2. Chronic hyperglycemia based on diabetes is independently associated with decreased survival in patients with advanced cancer treated with immune checkpoint inhibitors.
Yekedüz E; Köksoy EB; Yazgan SC; Karataş G; Şenler FÇ; Utkan G; Akbulut H; Demirkazik A; Ürün Y
Anticancer Drugs; 2022 Nov; 33(10):1145-1149. PubMed ID: 35946564
[TBL] [Abstract][Full Text] [Related]
3. Immune Checkpoint Inhibitor-Induced Diabetic Ketoacidosis: A Report of Four Cases and Literature Review.
Hong AR; Yoon JH; Kim HK; Kang HC
Front Endocrinol (Lausanne); 2020; 11():14. PubMed ID: 32047478
[TBL] [Abstract][Full Text] [Related]
4. Coexistence of Immune Checkpoint Inhibitor-Induced Autoimmune Diabetes and Pancreatitis.
Zhang AL; Wang F; Chang LS; McDonnell ME; Min L
Front Endocrinol (Lausanne); 2021; 12():620522. PubMed ID: 33927691
[TBL] [Abstract][Full Text] [Related]
5. Characteristics and risk factors for microbial infections during cancer immune checkpoint therapy.
Kanjanapan Y; Yip D
Cancer Med; 2020 Dec; 9(23):9027-9035. PubMed ID: 33159505
[TBL] [Abstract][Full Text] [Related]
6. Performance status and end-of-life care among adults with non-small cell lung cancer receiving immune checkpoint inhibitors.
Petrillo LA; El-Jawahri A; Nipp RD; Lichtenstein MRL; Durbin SM; Reynolds KL; Greer JA; Temel JS; Gainor JF
Cancer; 2020 May; 126(10):2288-2295. PubMed ID: 32142165
[TBL] [Abstract][Full Text] [Related]
7. [Immune Checkpoint Inhibitors Related Diabetes Mellitus:
A Report of 2 Cases and Literature Review].
Ren Y; Zhang L; Wang Y; Zhong D
Zhongguo Fei Ai Za Zhi; 2022 Jan; 25(1):61-65. PubMed ID: 35078286
[TBL] [Abstract][Full Text] [Related]
8. Ophthalmic Immune-Related Adverse Events after Anti-CTLA-4 or PD-1 Therapy Recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry.
Sun MM; Kelly SP; Mylavarapu Bs AL; Holland GN; Coleman AL; Yu F; Hsu Ms S; Lum F; Gordon LK
Ophthalmology; 2021 Jun; 128(6):910-919. PubMed ID: 33166553
[TBL] [Abstract][Full Text] [Related]
9. Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system.
Hu Y; Gong J; Zhang L; Li X; Li X; Zhao B; Hai X
Int Immunopharmacol; 2020 Jul; 84():106601. PubMed ID: 32422528
[TBL] [Abstract][Full Text] [Related]
10. Real-world adherence to toxicity management guidelines for immune checkpoint inhibitor-induced diabetes mellitus.
Shen M; Chen D; Zhao R; Zheng X; Gu Y; Yang T; Shi Y
Front Endocrinol (Lausanne); 2023; 14():1213225. PubMed ID: 37554766
[TBL] [Abstract][Full Text] [Related]
11. Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience.
Bhatlapenumarthi V; Patwari A; Harb AJ
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2789-2800. PubMed ID: 33774736
[TBL] [Abstract][Full Text] [Related]
12. Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors.
Aldrich J; Pundole X; Tummala S; Palaskas N; Andersen CR; Shoukier M; Abdel-Wahab N; Deswal A; Suarez-Almazor ME
Arthritis Rheumatol; 2021 May; 73(5):866-874. PubMed ID: 33258544
[TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoint Inhibitor-Associated Diabetes: A Single-Institution Experience.
Byun DJ; Braunstein R; Flynn J; Zheng J; Lefkowitz RA; Kanbour S; Girotra M
Diabetes Care; 2020 Dec; 43(12):3106-3109. PubMed ID: 33051330
[TBL] [Abstract][Full Text] [Related]
14. Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.
Chu X; Zhao J; Zhou J; Zhou F; Jiang T; Jiang S; Sun X; You X; Wu F; Ren S; Zhou C; Su C
Lung Cancer; 2020 Dec; 150():76-82. PubMed ID: 33080551
[TBL] [Abstract][Full Text] [Related]
15. Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside.
Wu L; Tsang VHM; Sasson SC; Menzies AM; Carlino MS; Brown DA; Clifton-Bligh R; Gunton JE
Front Endocrinol (Lausanne); 2021; 12():764138. PubMed ID: 34803927
[TBL] [Abstract][Full Text] [Related]
16. Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation.
Peeraphatdit TB; Wang J; Odenwald MA; Hu S; Hart J; Charlton MR
Hepatology; 2020 Jul; 72(1):315-329. PubMed ID: 32167613
[TBL] [Abstract][Full Text] [Related]
17. Encephalitis Induced by Immune Checkpoint Inhibitors: A Systematic Review.
Velasco R; Villagrán M; Jové M; Simó M; Vilariño N; Alemany M; Palmero R; Martínez-Villacampa MM; Nadal E; Bruna J
JAMA Neurol; 2021 Jul; 78(7):864-873. PubMed ID: 33720308
[TBL] [Abstract][Full Text] [Related]
18. Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer.
Zhou L; Wei X
Front Immunol; 2021; 12():701951. PubMed ID: 34504488
[TBL] [Abstract][Full Text] [Related]
19. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
[TBL] [Abstract][Full Text] [Related]
20. Association of prior fluoroquinolone treatment with survival outcomes of immune checkpoint inhibitors in Asia.
Lu PH; Tsai TC; Chang JW; Deng ST; Cheng CY
J Clin Pharm Ther; 2021 Apr; 46(2):408-414. PubMed ID: 33332621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
